1. Generics Bulletin
  2. >>Products

Reddy’s Exclusivity End Allows Teva, Natco To Match Full US Revlimid Suite

Controversial BMS Brand, Generics Challenged In Ongoing US Antitrust Suit

 
• By Dean Rudge

Teva has moved fast to match Dr Reddy’s Laboratories’ complete six-strength offering of generic Revlimid (lenalidomide) products in the US.

Open Book Of prostate multiple myeloma, Conceptual Image - Image
• Source: Shutterstock

With the launch of 2.5mg and 20mg strengths, Teva and its partner Natco Pharma now offer a complete portfolio of generic Revlimid (lenalidomide) capsules referencing the multiple myeloma powerhouse brand, following Dr Reddy’s Laboratories’ loss of exclusivity for the two strengths.

Teva had in March last year debuted generic lenalidomide capsules, but only in four strengths: 5mg, 10mg, 15mg, and 25mg. Its Arrow subsidiary had won approval for its ANDA in May 2021, with the potential for 180 days of generic market exclusivity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.